Table 3. Demographic and clinical details of patients with metastatic disease detected intraoperatively in spite of ‘M0’ restaging on PET-CT.
| Patient no | Age (y) | Sex | Tumor location | Tumor histology | AJCC stage [31] at baseline | Neoadjuvant regimen | Restaging PET-CT findings | Location & size of metastases | Esophagectomy cancelled due to intraoperative findings |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 66 | M | LT | Adenocarcinoma | 3A | 41.4 Gy, carboplatin, paclitaxel | Suspicion of metastasis 2nd rib (ruled out by biopsy) | Liver (10mm) | No |
| 2 | 52 | M | LT | Adenocarcinoma | 2B | 41.4 Gy, carboplatin, paclitaxel | Suspicion of metastasis cervical lymph node (ruled out by puncture) | Lung (6–7 mm) | Yes |
| 3 | 77 | M | LT | Adenocarcinoma | 1B | 41.4 Gy, carboplatin, paclitaxel | M0 | Liver (4-10mm) | Yes |
| 4 | 72 | M | EGJ | Adenocarcinoma | 3A | 41.4 Gy, carboplatin, paclitaxel | M0 | Multipele pleural lesions < 1 mm | Yes |
| 5 | 64 | M | EGJ | Adenocarcinoma | 3B | 41.4 Gy, carboplatin, paclitaxel | M0 | Liver (5–10 mm) | Yes |
| 6 | 75 | M | LT | Adenocarcinoma | 3B | 41.4 Gy, carboplatin, paclitaxel | Suspicion of metastasis left femur (ruled out by biopsy) | Lung (3–4 mm) | Yes |
Y, years; M, male; LT, lower thoracic; EGJ, esophagogastric junction; AJCC, American Joint Committee on Cancer; PET, positron emission tomography; CT, computed tomography